Hemoglobinopathy
MONDO:0044348Also known as: hemoglobinopathy, globin abnormality, haemoglobin disease, haemoglobin disorder, hemoglobin disease, hemoglobin disorder
445 clinical trials for this condition and its sub-types, 34 tagged with Hemoglobinopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Hemoglobinopathy
-
Inherited hemoglobinopathy 38 trials · 439 incl. sub-types
17 sub-types
- Sickle cell disease 342 trials Sub-types →
- Thalassemia 49 trials · 129 incl. sub-types Sub-types →
- Beta-thalassemia and related diseases 0 trials · 99 incl. sub-types Sub-types →
- Congenital nonspherocytic hemolytic anemia 1 trial · 12 incl. sub-types Sub-types →
- Sickle cell-beta-thalassemia disease syndrome 5 trials · 9 incl. sub-types Sub-types →
- Hemoglobin C disease 2 trials
- Hereditary methemoglobinemia 0 trials · 1 incl. sub-types Sub-types →
- Unstable hemoglobin disease 1 trial
- Hemoglobin D disease 0 trials
- Hemoglobin E disease 0 trials
- Hemoglobinopathy Toms River 0 trials
- Hereditary persistence of fetal hemoglobin 0 trials
- Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome 0 trials
- Homozygous hemoglobin O Arab disease 0 trials
- Sickle cell-hemoglobin E disease syndrome 0 trials
- Sickle cell-hemoglobin d disease syndrome 0 trials
- Sulfhemoglobinemia, congenital 0 trials
-
Methemoglobinemia 2 trials · 3 incl. sub-types
2 sub-types
- Hereditary methemoglobinemia 0 trials · 1 incl. sub-types Sub-types →
- Drug-induced methemoglobinemia 0 trials
-
Acquired hemoglobinopathy 0 trials
1 sub-type
- Drug-induced methemoglobinemia 0 trials
-
Sulfhemoglobinemia 0 trials
1 sub-type
- Sulfhemoglobinemia, congenital 0 trials
Most studied deeper sub-types
-
Can a One-Time gene infusion free patients from transfusions?
Cure Not yet recruitingThis trial tests a gene therapy called YOLT-204 in people aged 14 to 35 with sickle cell disease or transfusion-dependent thalassemia. The goal is to see if a single intravenous dose can safely boost fetal hemoglobin levels, potentially reducing or eliminating the need for blood …
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Selective cell removal may tame stem cell Transplant's dangerous side effect
Disease control Not yet recruitingThis study tests whether removing a specific type of immune cell (naive T cells) from a donor's stem cell graft can prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the recipient's body. The trial enrolls people with non-malignant blood di…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug YOLT-204 aims to reduce transfusions in blood disorders
Disease control Not yet recruitingThis early-phase trial will test a single dose of a new drug called YOLT-204 in 18 children and teens with transfusion-dependent β-thalassemia or sickle cell disease. The goal is to see if it is safe and can raise fetal hemoglobin levels enough to reduce the need for blood transf…
Early phase 1 • Sponsor: Guangzhou Women and Children's Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC